Short Interest in CalciMedica Inc. (NASDAQ:CALC) Drops By 54.9%

CalciMedica Inc. (NASDAQ:CALC) was the recipient of a large decline in short interest in the month of April. As of April 30th, there was short interest totaling 167,953 shares, a decline of 54.9% from the April 15th total of 372,157 shares. Currently, 1.8% of the company’s shares are short sold. Based on an average daily trading volume, of 151,788 shares, the short-interest ratio is currently 1.1 days.

Wall Street Analysts Forecast Growth

CALC has been the topic of several research analyst reports. Oppenheimer reduced their price objective on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating on the stock in a report on Thursday, March 5th. Wall Street Zen upgraded shares of CalciMedica to a “sell” rating in a research note on Saturday, January 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CalciMedica in a research note on Wednesday, January 21st. Finally, HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research note on Thursday, January 29th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $10.00.

CalciMedica Price Performance

Shares of CALC stock traded down $0.02 during trading hours on Friday, reaching $0.66. 237,629 shares of the stock were exchanged, compared to its average volume of 135,032. The business’s fifty day moving average is $0.64 and its two-hundred day moving average is $2.51. CalciMedica has a 12-month low of $0.46 and a 12-month high of $7.20. The firm has a market capitalization of $10.38 million, a P/E ratio of -0.50 and a beta of 0.85.

CalciMedica (NASDAQ:CALC) last released its earnings results on Tuesday, March 3rd. The company reported ($0.69) earnings per share for the quarter. As a group, equities research analysts predict that CalciMedica will post -1.21 earnings per share for the current fiscal year.

Institutional Trading of CalciMedica

A number of large investors have recently made changes to their positions in CALC. Cetera Investment Advisers increased its stake in shares of CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after buying an additional 9,045 shares during the period. 180 Wealth Advisors LLC raised its holdings in CalciMedica by 297.2% during the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after purchasing an additional 94,650 shares in the last quarter. Renaissance Technologies LLC raised its holdings in CalciMedica by 45.0% during the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after purchasing an additional 39,775 shares in the last quarter. Jane Street Group LLC acquired a new stake in CalciMedica during the fourth quarter worth approximately $127,000. Finally, Envestnet Asset Management Inc. boosted its holdings in shares of CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after buying an additional 34,386 shares in the last quarter.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.